Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants
Clinical and Translational Science · 2026
DOI: 10.1111/cts.70476 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Jason D Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C9, Alkynes, Benzoxazines, Cytochrome P-450 CYP2C9 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe. Healthy participants received a single oral dose of tolbutamide (250 mg) with a single 600 mg dose of efavirenz (SD) before and after 600 mg daily efavirenz for 17 days (MD). Tolbutamide, efavirenz, and their metabolites were quantified in plasma and urine samples by LC–MS/MS method. Participants were genotyped for CYP2C9*2 and *3 and for CYP2B6*4, *9, and *18. Pharmacokinetic data were valid for 71 and 59 participants for SD‐ and MD groups, respectively. MD efavirenz caused more than 50% increase in median tolbutamide AUC 0‐∞ and C 24 in all subjects, and 1.42–1.46‐fold increase in the paired analysis ( p < 0.0001); tolbutamide/metabolite ratios were also increased ( p < 0.001), while tolbutamide's CL/F/kg, metabolite formation clearance, and metabolite C max were significantly reduced. CYP2C9 genetic variants were associated with reduced tolbutamide elimination compared to *1/*1 and *1/*2 (slowest, *3/*3; and intermediate, *1/*3, *2/*2, and *2/*3). The lowest percent change occurred in *2/*2 and * 3/*3 genotypes, though small sample sizes limited reliable assessment of genotype‐specific DDI effects. In conclusion, chronic efavirenz use inhibits CYP2C9 activity in vivo. This inhibition may increase the risk of adverse effects from narrow‐therapeutic‐index CYP2C9 substrates (e.g., warfarin, phenytoin, and sulfonylureas). Therefore, therapeutic drug monitoring and dose adjustments are warranted when efavirenz is co‐administered with these medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Department of Pharmacy, Faculty of Health Sciences, Universidade de Brasília, Federal District, Brazil.
ORCID-Profile: Jason D Kim, Ingrid F Metzger, Todd C Skaar, Zeruesenay Desta
Förderung
- NIGMS NIH HHS
Zitieren
APA
Kim, J. D., Metzger, I. F., Lu, J. B. L., Skaar, T. C., & Desta, Z. (2026). Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants. Clinical and Translational Science. https://doi.org/10.1111/cts.70476
Vancouver
Kim JD, Metzger IF, Lu JBL, Skaar TC, Desta Z. Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants. Clinical and Translational Science. 2026. doi:10.1111/cts.70476
BibTeX
@article{Kim2026,
author = {Kim, Jason D and Metzger, Ingrid F and Lu, Jessica Bo Li and Skaar, Todd C and Desta, Zeruesenay},
title = {Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants},
journal = {Clinical and Translational Science},
year = {2026},
doi = {10.1111/cts.70476}
}
EUVIMED